Recent Updates — VCRE

The independent Data Monitoring Committee for Vicore Pharma Holding AB's Phase 2b ASPIRE trial recommended the study continue without modification after a pre-planned futility analysis. The trial, which enrolled 378 patients with idiopathic pulmonary fibrosis, assessed the change from baseline in forced vital capacity at Week 52 for buloxibutid versus placebo. No safety concerns were identified during the review of data from approximately 100 randomized patients who completed 52 weeks of treatment or discontinued. The company remains blinded to quantitative results and expects topline results in mid-2027, with cash runway extending into the second half of 2028. Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing angiotensin II type 2 receptor agonists for respiratory and fibrotic diseases.

Vicore Pharma Holding AB reported unaudited financial results for the second quarter ended June 30, 2026. The company completed patient recruitment in its Phase 2b ASPIRE trial evaluating buloxibutid for idiopathic pulmonary fibrosis (IPF), enrolling over 360 patients across 14 countries ahead of schedule, with topline results expected in mid-2027. Financially, net revenues were SEK 2.2 million and operating loss was SEK 150.1 million for the quarter. Cash and short-term investments stood at SEK 905.6 million (USD 93.0 million) as of June 30, providing a runway into late 2028. Post-period, Vicore commenced dual listing on Nasdaq Capital Market under ticker VCRE in July and appointed Rob Slack as Chief Scientific Officer. Vicore Pharma is a clinical-stage biopharmaceutical company developing angiotensin II type 2 receptor agonists for respiratory and fibrotic diseases.